One study evaluated two different genetic therapies—an adenine base editor (ABE8e) and a potent Cas9 nuclease—both delivered via AAV9 (Adeno Associated Virus serotype 9) to prevent disease in mice with heterozygous HCM PV, myosin R403Q. The gene discussed is MYH14; the disease is acquired polycythemia vera.